Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 17, Issue 8, Pages 887-902Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17425255.2021.1894122
Keywords
Cardiotoxicity; new approach methods; drugs; environmental chemicals
Funding
- National Institutes of Health [P42 ES027704, T32 ES026568, STAR RD83580201]
Ask authors/readers for more resources
iPSC-derived cardiomyocytes are valuable in improving the accuracy, precision, and efficiency of cardiotoxicity hazard identification for drugs and non-pharmaceuticals. Efforts are underway to demonstrate their utility in risk characterization, but challenges remain in cell maturation, understanding their use in identifying structural cardiotoxicity, and expanding case studies for population-wide and disease-specific risk characterization. Ultimately, iPSC-derived cardiomyocytes have great potential for enhancing cardiotoxicity testing for non-pharmaceutical chemicals.
Introduction Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes is one of the most widely used cell-based models that resulted from the discovery of how non-embryonic stem cells can be differentiated into multiple cell types. In just one decade, iPSC-derived cardiomyocytes went from a research lab to widespread use in biomedical research and preclinical safety evaluation for drugs and other chemicals. Areas covered This manuscript reviews data on toxicology applications of human iPSC-derived cardiomyocytes. We detail the outcome of a systematic literature search on their use (i) in hazard assessment for cardiotoxicity liabilities, (ii) for risk characterization, (iii) as models for population variability, and (iv) in studies of personalized medicine and disease. Expert opinion iPSC-derived cardiomyocytes are useful to increase the accuracy, precision, and efficiency of cardiotoxicity hazard identification for both drugs and non-pharmaceuticals, with recent efforts beginning to demonstrate their utility for risk characterization. Notable limitations include the needs to improve the maturation of cells in culture, to better understand their potential use identifying structural cardiotoxicity, and for additional case studies involving population-wide and disease-specific risk characterization. Ultimately, the greatest future benefits are likely for non-pharmaceutical chemicals, filling a critical gap where no routine testing for cardiotoxicity is currently performed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available